Follicular Lymphoma (FL): Clinical Trials

9 trials for Follicular Lymphoma (FL), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 not yet recruiting, 3 terminated, 2 recruiting, 1 completed. 9 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Not yet recruiting 3, Terminated 3, Recruiting 2, Completed 1
Phase 14Terminated 2, Completed 1, Recruiting 1

Follow Follicular Lymphoma (FL): new trials by email Literature Review of Follicular Lymphoma (FL) trials Research Report on Follicular Lymphoma (FL)

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma
Sotoclax in combination with zanubrutinib and rituximab regimen - Follicular Lymphoma (FL)
Phase 2Not yet recruitingSun Yat-sen University522026-09-012026-04-24
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
MDX2003 - Lymphoma, Waldenström Macroglobulinemia (WM)
Phase 1 / Phase 2RecruitingModeX Therapeutics, An OPKO Health Company1802026-04-132026-11-06
Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma
TC011 single-arm - Follicular Lymphoma (FL)
Phase 2Not yet recruitingTICAROS Co., Ltd.402026-03-012026-01-22
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
Zuberitamab, Bendamustine - Follicular Lymphoma (FL)
Phase 2Not yet recruitingSun Yat-sen University502025-02-012025-01-03
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Surovatamig - B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL)
Phase 2RecruitingAstraZeneca2702024-11-272026-10-14
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
Phase 1 / Phase 2TerminatedMingSight Pharmaceuticals, Inc82023-02-062024-07-18
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Zandelisib (ME-401) - Follicular Lymphoma (FL), Non Hodgkin Lymphoma
Phase 2TerminatedMEI Pharma, Inc.1692019-06-252024-12-31
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
Tazemetostat - Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
Phase 1 / Phase 2TerminatedEpizyme, Inc.582016-08-302026-10-28
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL
Phase 1 / Phase 2CompletedAcerta Pharma BV1612015-02-202026-05-13

Narrower conditions

Lymphoma, Follicular (9)  ·  Lymphoma, B-Cell, Marginal Zone (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Recurrence (2)  ·  Waldenstrom Macroglobulinemia (2)  ·  Burkitt Lymphoma (1)  ·  Dendritic Cell Sarcoma, Interdigitating (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Hairy Cell (1)  ·  Lymphoma (1)  ·  Mesothelioma (1)

Broader conditions

Hemic and Lymphatic Diseases (9)  ·  Immune System Diseases (9)  ·  Immunoproliferative Disorders (9)  ·  Lymphatic Diseases (9)  ·  Lymphoproliferative Disorders (9)  ·  Neoplasms (9)  ·  Neoplasms by Histologic Type (9)  ·  Lymphoma (8)  ·  Lymphoma, Non-Hodgkin (6)  ·  Lymphoma, B-Cell (4)  ·  Disease Attributes (3)  ·  Hematologic Diseases (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Blood Protein Disorders (2)

Interventions

Bendamustine Hydrochloride (1)  ·  ME-401 (1)  ·  acalabrutinib (1)  ·  pembrolizumab (1)  ·  tazemetostat (1)  ·  zanubrutinib (1)

Sponsors

Sun Yat-sen University (2)  ·  Acerta Pharma BV (1)  ·  AstraZeneca (1)  ·  Epizyme, Inc. (1)  ·  MEI Pharma, Inc. (1)  ·  MingSight Pharmaceuticals, Inc (1)  ·  ModeX Therapeutics, An OPKO Health Company (1)  ·  TICAROS Co., Ltd. (1)

Countries

Australia (4)  ·  China (4)  ·  United States (4)  ·  France (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Germany (2)  ·  Italy (2)  ·  Poland (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Austria (1)  ·  Brazil (1)  ·  Canada (1)

Top investigators

Qingqing Cai (1)  ·  Won Seok Kim, MD, PhD (1)

NIH funding

2023 (2), 2015 (1), 2018 (1)